FY2025 Earnings Estimate for DexCom Issued By William Blair

DexCom, Inc. (NASDAQ:DXCM) – William Blair dropped their FY2025 earnings per share (EPS) estimates for shares of DexCom in a note issued to investors on Friday, October 31st. William Blair analyst B. Vazquez now expects that the medical device company will post earnings per share of $2.05 for the year, down from their prior forecast of $2.06. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.66 EPS, Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.45 EPS, Q1 2027 earnings at $0.67 EPS, Q2 2027 earnings at $0.71 EPS, Q3 2027 earnings at $0.75 EPS and FY2027 earnings at $2.90 EPS.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm posted $0.45 EPS. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS.

Several other brokerages have also recently issued reports on DXCM. UBS Group lowered their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday. Morgan Stanley lifted their target price on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. Truist Financial reaffirmed a “buy” rating and set a $82.00 target price (down previously from $94.00) on shares of DexCom in a research note on Monday. Finally, Royal Bank Of Canada lowered their target price on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.33.

DexCom Trading Up 1.2%

Shares of DXCM opened at $61.18 on Monday. DexCom has a 52-week low of $56.44 and a 52-week high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm’s fifty day moving average is $70.33 and its two-hundred day moving average is $77.91. The stock has a market cap of $23.99 billion, a PE ratio of 42.49, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,383 shares of company stock worth $434,274 in the last quarter. 0.32% of the stock is currently owned by insiders.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Allianz Asset Management GmbH increased its position in shares of DexCom by 84.2% during the 3rd quarter. Allianz Asset Management GmbH now owns 103,317 shares of the medical device company’s stock worth $6,952,000 after purchasing an additional 47,234 shares during the last quarter. Peterson Wealth Services increased its position in shares of DexCom by 423.6% during the 3rd quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock worth $1,947,000 after purchasing an additional 23,410 shares during the last quarter. Atlantic Union Bankshares Corp increased its position in shares of DexCom by 518.5% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 4,948 shares of the medical device company’s stock worth $333,000 after purchasing an additional 4,148 shares during the last quarter. AGF Management Ltd. acquired a new stake in shares of DexCom during the 3rd quarter worth about $657,000. Finally, State of Wyoming increased its position in shares of DexCom by 437.8% during the 3rd quarter. State of Wyoming now owns 4,265 shares of the medical device company’s stock worth $287,000 after purchasing an additional 3,472 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.